GlassScriptPhysician profile
Ali Hafiz
NPI 1417361452
$16,400.72
in general payments reported to CMS, 2019-2025
38 companies · $3,751 in 2025
The $3,751 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $1,731 · 2023: $2,331 · 2024: $8,295 · 2025: $3,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,711 · Education: $6,349 · Travel and Lodging: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,711.24 |
| Education | $6,349.42 |
| Travel and Lodging | $1,316.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,802.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,367.54 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,221.08 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ani Pharmaceuticals, INC. | $857.60 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.81 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $613.75 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Olympus Corporation of The Americas | $590.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $514.14 | 2021-2025 | Glassia, Cuvitru |
| Genzyme Corporation | $393.99 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $381.59 | 2021-2024 | Dupixent |
| United Therapeutics Corporation | $328.44 | 2022-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $319.54 | 2022-2025 | Tezspire |
| Insmed, INC. | $297.64 | 2023-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $284.04 | 2024-2025 | Acthar |
| Harmony Biosciences LLC | $258.21 | 2023-2025 | Wakix |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $189.43 | 2022-2025 | |
| Grifols USA, LLC | $181.98 | 2023-2025 | Prolastin-C Liquid |
| Shionogi INC | $173.23 | 2025 | Fetroja |
| Lilly USA, LLC | $121.93 | 2025 | Zepbound |
| Electromed, INC. | $111.06 | 2024-2025 | Smartvest |
| Astellas Pharma US INC | $108.86 | 2024 | Cresemba |
| Axsome Therapeutics, INC. | $86.79 | 2024-2025 | Sunosi |
| Verona Pharma, INC. | $79.18 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Vifor Pharma, INC. | $53.71 | 2024-2025 | Zemaira |
| Paratek Pharmaceuticals, INC. | $39.33 | 2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $38.05 | 2022-2023 | Quviviq |
| Pfizer INC. | $34.56 | 2023 | |
| Pulmonx Corporation | $34.01 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Vanda Pharmaceuticals INC. | $32.13 | 2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $25.44 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Mylan Specialty L.P. | $24.95 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $22.81 | 2021 | |
| Viatris Specialty LLC | $20.74 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $16.99 | 2024 | Lumryz |
| Gilead Sciences, INC. | $16.39 | 2021 | |
| Olympus America INC. | $13.42 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hafiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.